DESTINY-LUNG02

NCT04644237 📎

Regimen

Experimental
Trastuzumab deruxtecan 6.4 mg/kg
Control
Trastuzumab deruxtecan 5.4 mg/kg

Population

previously platinum-treated HER2-mutant metastatic NSCLC

Key finding

Final analysis — 5.4 mg/kg preferred dose, better tolerability with similar efficacy.

Source: PMID 37694347

Timeline

  • Enrollment start: 2021-03-19 📎

Guideline citations

  • CSCO NSCLC 2025 ⚠️ OCR source